You are here

Vascular & Endovascular

 

The alternative smoking trend that’s taking over international markets might be more dangerous than tobacco companies are letting on—heat-not-burn tobacco’s negative impact on blood vessel function matches the damage done by smoking regular cigarettes, the American Heart Association reported at its Scientific Sessions 2017.

A simple, inexpensive tool could predict healthy individuals’ future risk of cardiovascular disease through just five painless calculations, Mount Sinai Health System reported today in a novel study. The paper was simultaneously published in the Journal of the American College of Cardiology.

Black men are most likely to suffer from intracranial atherosclerotic disease (ICAD), an important contributor to stroke, while midlife risk factors for the illness vary between blacks and whites, according to a new study published in JAMA Cardiology.

Five-minute interventions, “quit kits” and information delivered by peers all proved to be successful strategies for getting through to young smokers, research out of the University of California-Davis reports.

A new lab technique could cut testing time and improve the accuracy of coronary artery disease (CAD) diagnoses, new research published in Radiology states.

 

Recent Headlines

ADA: Alegitazar could be new treatment for type 2 diabetes A new treatment for type 2 diabetes using aleglitazar could be safe and effective and thus will be entered into phase III trials, according to the phase II SYNCHRONY study published June 8 in Lancet, and simultaneously presented at the American Diabetes Association (ADA) meeting in New Orleans.
Medtronic acquires diabetes monitoring tool from Danish company Medtronic has purchased substantially all glucose monitoring assets from PreciSense, a Horsholm, Denmark-based development company focused on continuous glucose monitoring technology. Terms of theacquisition were not disclosed.
Vascular Solutions offers new line of guidewires Vascular Solutions has launched its new Muskie line of 0.014-inch guidewires, which offer a range of distal tip stiffness that allows physicians to select an appropriate guidewire for crossing stenosed lesions.
Pathway Medical raises $42.5M in series D financing WRF Capital, the venture investment arm of the nonprofit Washington Research Foundation (WRF), has invested $1.5 million as part of Pathway Medical Technologies' Series D round of financing. The foundations investment brings the total series D round to $42.5 million.
Lilly, Medtronic ink marketing diabetes pact Eli Lilly and Medtronic have formed a strategic marketing collaboration to bolster each company to help people with diabetes manage their blood sugar using insulin therapy.
Momentum Builds for Lower Extremity Stenting

Newer iterations of stents have contributed to better outcomes in the iliac and superficial femoral arteries, prompting cardiologists to take notice.

C.R. Bard posts 44% increase in net income C. R. Bard has reported growth in net income and net sales for its 2009 first quarter driven by reductions in distributor inventory and by managing expenses.
Vascular Programs Can Bring New Business Opportunities Initiating a vascular program into your practice has its challenges, but in this economy, its a move that should be pursued, says John O. Goodman, in a commentary appearing in this Endovascular Portal.

Hospitals and practices are reviewing all phases of their operations to determine what can be eliminated or streamlined for better efficiencies. In these tight economic times, many administrators are not even thinking about adding services to their programs. This is the perfect time, however, to consider pulling in some business from a previously unexplored patient base.
Commentary: Its time to increase your vascular revenue Today, most hospitals and healthcare systems consider a cardiovascular program to be their heart program. A recent industry survey asked healthcare leaders, In your opinion, which service line today has the greatest potential to produce strong revenue growth within the next three years? Not surprisingly, cardiology (i.e., heart disease) topped the list at 15 percent, while vascular received only 2 percent of votes.1
Cardiovascular Systems completes $37M merger with Replidyne Cardiovascular Systems has completed its merger with Replidyne, a Louisville, Colo.-based biotech firm.

Pages